In May, the Trump Administration issued its “American Patients First” drug pricing blueprint, aimed at improving competition and lowering both list prices and out-of-pocket costs for prescription drugs. In recent months, the Administration has been at work preparing proposals aimed at bringing about changes promised in the Blueprint, including with respect to the Anti-Kickback Statute, the Medicare Part D drug benefit, and drug pricing transparency in Medicare and Medicaid. This session will discuss the implications of these proposals for drug manufacturers, PBMs, and payers, as well as further changes that may be forthcoming in 2019 both from the Administration and from Congress. The discussion will include the impact of the 2018 midterm elections on the shape of drug pricing policy in the next two years.
Please note that in addition to the speakers listed below, we also intend to invite Kirstin Bass, Senior Vice President, Policy and Federal Affairs, PCMA
Ability Level: Intermediate
Session ID: 503640